D-Wave Quantum Inc. (NYSE: QBTS) Providing Quantum Applications for Life Sciences Industry With Potential to Transform Discovery, Production, and More

  • Quantum computing provides companies with promising new technologies that have the potential to streamline the drug development and patient trial processes, potentially finding greater efficiencies than classical computing systems
  • D-Wave has demonstrated that annealing quantum computers could play a transformational role in the life sciences industry, as illustrated by the company’s work with Menten AI and its achievements in protein design

The life sciences industry is centered around researching, developing, and manufacturing products to improve the lives of humans – including drug discovery. Drug discovery is a high-risk, high-reward field that helps to deliver life-changing clinical benefits to millions of patients.

Through quantum computing, pharma and biotech companies may be able to stack the odds in their favor through promising new technologies. D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems and software, focused on delivering customer value via practical quantum applications, offers quantum hybrid solutions for companies within the life sciences industry. In a recent survey by the Quantum Economic Development Consortium, 82% of life sciences organizations agreed that quantum computing would have a commercial impact within the decade. Nearly one-third of respondents stated they would begin evaluating such systems within the year (https://ibn.fm/T0uSZ).

D-Wave has begun to illustrate the power that quantum computing can have on the life sciences industry through its use case with Menten AI, a company reimagining biology through quantum-powered protein design. Menten AI is harnessing the unique capabilities of quantum computers to transform the traditional trial-and-error process of relying on undirected, blind screenings of random mutations. Menten AI is taking the first steps with D-Wave to incorporate quantum hybrid computing into the process, accelerating the time to solution.

In 2020, Menten AI announced the development of the first successful process using quantum hybrid programs to determine protein structure for de novo protein design. These unique designs have been computationally validated, chemically synthesized, and are being advanced to live-virus testing against COVID-19.

“Using hybrid quantum applications, we’re able to solve astronomical protein design problems. We’ve seen extremely encouraging results, with hybrid quantum procedures often finding better solutions than competing classical solvers for de novo protein design,” said Hans Melo, CEO and Co-Founder of Menten AI (https://ibn.fm/SvU2X). “This means we can create better proteins and ultimately enable new drug discoveries.”

Through machine learning and quantum computing, Menten AI has gained a competitive edge in designing and engineering proteins for applications in the pharmaceutical and chemical industries – creating designer proteins that may one day be useful in a variety of therapeutics. By extending the capabilities of its protein design and structure software and interfacing it with D-Wave’s quantum processor, Menten AI researchers were able to leverage quantum annealing for their protein design problems.

D-Wave is the only company building both annealing and gate-model quantum computing systems. The company works with life sciences organizations to identify the problems best suited for quantum, trains teams to start the development process, moves applications to test so that they are ready for market, and gets the application up and running to deliver benefits to the industry, and ultimately, society.

To check out more examples of how D-Wave is helping companies in all industries use quantum computing to solve complex problems, check out customer success stories here: https://ibn.fm/OZYNo.

For more information, visit the company’s website at www.DWaveSys.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

About BillionDollarClub

BillionDollarClub (BDC) is the exclusive home of the biggest and brightest companies covered by IBN, a financial news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution to millions of social media followers, and (5) a full array of corporate communications solutions. This is the place you want to be, where every covered company has a market cap in excess of $1 billion. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled visibility, recognition and brand awareness. While IBN’s client list includes companies big and small, BillionDollarClub is the gold standard.

To receive SMS text alerts from BillionDollarClub, text “Billion” to 888-902-4192  (U.S. Mobile Phones Only)

For more information, please visit https://www.BillionDollarClub.com

Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: http://IBN.fm/Disclaimer

BillionDollarClub (BDC)
Los Angeles, California
310.299.1717 Office

BillionDollarClub is part of the InvestorBrandNetwork.


Select A Month

Contact us: (310) 299-1717